Comparison of intramuscular progesterone and suppository progesterone for luteal phase support in IUI cycles

Phase 2

Conditions: luteal phase support in IUI cycles.

Registration Number: IRCT2015030521344N1

Lead Sponsor: Vice Chancellor for Research and Technology, Semnan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 312

Inclusion Criteria

age 20-38yr,period of infertility more than 1year.with unexplained or male factor infertility undergoing IUI cycle were included.
With normal Thyroid- stimulating- Hormone (TSH) and prolactin levels.
Bilateral patent tubes at HSG or laparoscopy, normal hormonal assay in the early follicular phase, and normal sperm count, motility, and morphology according to the World Health Organization (WHO 1992) criteria for unexplained infertility.
In male-factor infertility cases, the total motile sperm count had to be > 1 million to be considered eligible to enter the study

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Pregnancy. Timepoint: 5 Weeks after IUI. Method of measurement: Trans vaginal sonography will be done at 5 weeks after IUI.

Secondary Outcome Measures

Name	Time	Method
Abortion and twin pregnancy. Timepoint: From confirmed pregnancy to12 weeks of gestation . Method of measurement: Sonography.;Ongoing pregnancy. Timepoint: From confirmed pregnancy to12 weeks of gestation . Method of measurement: Vaginal sonography.;The satisfaction and convenience rate between vaginal progesterone and IM progesterone. Timepoint: From confirmed pregnancy to8 weeks of gestation. Method of measurement: Using a scale of 1-3, with 3 being very satisfied, convenient; 2 being satisfied, convenient; and 1 being unsatisfied, not convenient.;Side effects of vaginal and IM progestrone. Timepoint: From confirmed pregnancy to8 weeks of gestation. Method of measurement: Vaginal itching , discharge and pain and swelling on the injection site .